Radiation therapy

iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19

Monday, June 1, 2020 - 1:00pm

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy, on June 4, 2020 at 7 pm ET/4 pm PT.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy, on June 4, 2020 at 7 pm ET/4 pm PT.
  • Xoft breast IORT is a single-fraction therapy option that allows select early-stage breast cancer patients to replace weeks of daily radiation with one treatment, delivered at the time of surgery.
  • A number of breast cancer patients at our facility have had their treatment delayed due to the COVID-19 pandemic.
  • This virtual roundtable event is a part of larger series of webinars hosted by iCAD in recent weeks, featuring leading experts in breast cancer detection and treatment.

Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020

Friday, May 29, 2020 - 5:02pm

The data were published as part of the virtual scientific program at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO).

Key Points: 
  • The data were published as part of the virtual scientific program at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO).
  • To date, 40 patients have been recruited, 30 of whom are evaluable for efficacy and are included in the data presented at ASCO 2020.
  • Regarding the new, expansion part data, analysis of 40 patients dosed showed that NBTXR3 activated by radiation therapy remains safe and well tolerated.
  • In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers.

RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA® for Certain Late-Stage Cancers

Thursday, May 28, 2020 - 2:00pm

This image depicts two 90-degree PET arcs that sense tumor emissions to guide radiotherapy delivery.

Key Points: 
  • This image depicts two 90-degree PET arcs that sense tumor emissions to guide radiotherapy delivery.
  • Worldwide, over 1,000 clinical trials registered with the National Institutes of Health seek to determine the effect of combining immunotherapy and radiotherapy.
  • Currently, the RefleXion machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT), all different techniques of EBRT.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Humanetics Corporation to Present Clinical Trial Results at the Annual Meeting of the American Society for Radiation Oncology

Thursday, May 28, 2020 - 2:54pm

Humanetics Corporation (Humanetics) today announced that an abstract reporting the results of a clinical trial of BIO 300 in non-small cell lung cancer patients undergoing radiochemotherapy has been selected for oral presentation at the annual meeting of the American Society for Radiation Oncology taking place virtually from October 25-28, 2020.

Key Points: 
  • Humanetics Corporation (Humanetics) today announced that an abstract reporting the results of a clinical trial of BIO 300 in non-small cell lung cancer patients undergoing radiochemotherapy has been selected for oral presentation at the annual meeting of the American Society for Radiation Oncology taking place virtually from October 25-28, 2020.
  • More than 3,300 abstracts were submitted to the premier international radiation oncology annual meeting, and Humaneticss abstract was one of only 280 selected for this highest level of oral presentation.
  • However, radiation therapy can cause unwanted side effects to otherwise healthy tissue surrounding the tumor or in the path of the radiation beam.
  • Humanetics acquired the rights to the drug and has active development programs ongoing in both oncology and for biodefense.

RaySearch Enters Into Interoperability Agreement With Varian

Thursday, May 28, 2020 - 12:23pm

STOCKHOLM, May 28, 2020 /PRNewswire/ -- RaySearch Laboratories AB (publ) and Varian Medical Systems have entered into an interoperability agreement that will allow the RayCare* oncology information system to connect to Varian TrueBeam linear accelerators.

Key Points: 
  • STOCKHOLM, May 28, 2020 /PRNewswire/ -- RaySearch Laboratories AB (publ) and Varian Medical Systems have entered into an interoperability agreement that will allow the RayCare* oncology information system to connect to Varian TrueBeam linear accelerators.
  • Under the announced agreement, a dedicated interface has been defined which allows RayCare and Varian TrueBeam to communicate the data necessary for an integrated workflow.
  • This means that clinics will be able to use RayCare to manage all clinical activities around their Varian TrueBeam accelerators.
  • Interoperability with Varian TrueBeam will significantly expand the market potential for RayCare and improve the workflow for our existing customers."

Montefiore Medical Center to Partner With Siris Medical to Implement AI Decision Support Platform to Inform Patient Outcomes and Ensure High Quality Cancer Treatment

Tuesday, May 19, 2020 - 3:00pm

Montefiore will implement Siris's InsightRT software platform to offer Clinical Decision Support and provide insight into patient-specific treatment outcomes prior to initiating treatment.

Key Points: 
  • Montefiore will implement Siris's InsightRT software platform to offer Clinical Decision Support and provide insight into patient-specific treatment outcomes prior to initiating treatment.
  • "In my career, having more accurate insights into patient outcomes is key to so many decisions that we share with our patients.
  • This innovation will be embraced by both caregivers and patients alike for its positive impact on patient care and the patient experience," said Marc Nash MD, Chief Medical Officer of Siris Medical.
  • Siris Medical empowers clinicians to achieve efficient high-quality cancer radiation treatment decisions through its artificial intelligence platform, InsightRT, the first commercial decision-support system in radiation oncology.

Varian Announces New Addition to FlashForward Consortium

Monday, May 18, 2020 - 1:15pm

Now including 20 members, representing nine countries, the Consortiumis focused on preclinical research, clinical implementation, and advocacy efforts of FLASH therapy.

Key Points: 
  • Now including 20 members, representing nine countries, the Consortiumis focused on preclinical research, clinical implementation, and advocacy efforts of FLASH therapy.
  • Varian is installing a Varian ProBeam Compact system equipped with a 360-degree gantry and integrated cone beam CT at Proton Therapy Pte., Ltd.'s site in Singapore.
  • "We are proud to welcome Proton Therapy Pte., Ltd. to the FlashForward Consortium," said Kolleen Kennedy, chief growth officer and president of Proton Therapy Solutions, Varian.
  • "Representing our first member from Southeast Asia, they are a significant new addition to the Consortium.

Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Monday, May 18, 2020 - 1:30pm

PyL is the Companys PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.

Key Points: 
  • PyL is the Companys PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.
  • 63.9% of patients in the CONDOR trial had a change in intended disease management plans due to PyL imaging results, a key secondary endpoint of the trial.
  • Consistent with the Phase 2 OSPREY trial results, safety results showed that PyL was well tolerated.
  • The full positive results of our Phase 3 CONDOR trial continue to validate our beliefs in PyL to potentially alter the way physicians treat prostate cancer.

Analysis on Impact of COVID19-Brachytherapy Devices Market 2020-2024 | High Prevalence of Cancer to Boost Growth | Technavio

Monday, May 18, 2020 - 8:30am

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43465

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43465
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our brachytherapy devices market report covers the following areas:
    This study identifies increase in M&A and strategic alliances among vendors as the prime reasons driving the brachytherapy devices market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the brachytherapy devices market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Hitachi's First Proton Therapy System in Europe Opens at Clinica Universidad de Navarra in Spain

Friday, May 8, 2020 - 2:22am

Clinica Universidad de Navarra is the first hospital which Hitachi has delivered the whole proton therapy system in Europe.

Key Points: 
  • Clinica Universidad de Navarra is the first hospital which Hitachi has delivered the whole proton therapy system in Europe.
  • The proton therapy system installed at Clinica Universidad de Navarra is equipped with state-of-the-art technology including spot scanning technology that sends a therapeutic proton beam precisely conforming to the shape of the target tumor.
  • And it has a 360degree rotating gantry treatment room with cone beam CT(1) and Real-time image Gated Proton Therapy (RGPT)(2) capability.
  • Clinica Universidad de Navarra, based in Navarra and Madrid, Spain, is a world-class private hospital focusing on medical research, education and clinical care.